It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

Glaxo Wellcome agreed to pay the University royalties on the worldwide sale of Ziagen, an AIDS-inhibiting drug, University President Mark Yudof announced Tuesday. About two-thirds of the royalty ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Rick Ware became a NASCAR Cup team owner first. Then he expanded into the NHRA, American Flat Track motorcycle racing and FIM World Supercross. Ware’s weekend travel schedule is dictated by ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...